Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET
Company Participants
Alex Dasalla - Head of IR & Corporate Communications
Joe Ciaffoni - President and CEO
Colleen Tupper - CFO
Scott Dreyer - CCO
Conference Call Participants
David Amsellem - Piper Sandler
Lachlan Hanbury-Brown - William Blair
Serge Belanger - Needham & Co.
Greg Fraser - Truist Securities
Brandon Folkes - Cantor Fitzgerald
Operator
Greetings, and welcome to Collegium Pharmaceutical, Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Alex Dasalla. Thank you. Please go ahead.
Alex Dasalla
Thank you, operator. Welcome to Collegium Pharmaceuticals first quarter 2022 earnings conference call. This is Alex Dasalla, Head of Investor Relations at Collegium Pharmaceutical. I'm joined today by Joe Ciaffoni, our Chief Executive Officer; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer. They will share some prepared remarks, and then we will take your questions.
Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to derive the expected benefits of our recently completed acquisition of BioDelivery Sciences International, on the proposed schedule or at all, that we may not be able to successfully renegotiate our contracts related to Xtampza ER prescriptions on desired terms, that we may not be able to successfully commercialize our products and that we may incur significant expense and may not prevail in current or future patent infringement litigation or other litigation pertaining to our products.
These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today.
Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations on our corporate website at collegiumpharma.com.
I will now turn the call over to Collegium's CEO, Joe Ciaffoni.